These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8674161)

  • 1. Biological characterization of L-asparaginase liposomal formulations.
    Gaspar MM; Perez-Soler R; Cruz ME
    Cancer Chemother Pharmacol; 1996; 38(4):373-7. PubMed ID: 8674161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal palmitoyl-L-asparaginase: characterization and biological activity.
    Jorge JC; Perez-Soler R; Morais JG; Cruz ME
    Cancer Chemother Pharmacol; 1994; 34(3):230-4. PubMed ID: 8004756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved pharmacological profile of the lipophilic antitumor dichloro-(N-dodecyl)-propanediamine-platinum(II) complex after incorporation into pegylated liposomes.
    Silva H; Silva AC; Lemos FO; Monte-Neto RL; Fontes AP; Lopes MT; Frézard F
    Anticancer Drugs; 2013 Feb; 24(2):131-9. PubMed ID: 23011234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipophilic cisplatin analogues entrapped in liposomes: role of intraliposomal drug activation in biological activity.
    Perez-Soler R; Khokhar AR
    Cancer Res; 1992 Nov; 52(22):6341-7. PubMed ID: 1423280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The liposomal formulation of doxorubicin.
    Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
    Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gel entrapped L-asparaginase: kinetic behavior and antitumor activity.
    O'Driscoll KF; Korus RA; Ohnuma T; Walczack IM
    J Pharmacol Exp Ther; 1975 Nov; 195(2):382-8. PubMed ID: 241845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice.
    Newman MS; Colbern GT; Working PK; Engbers C; Amantea MA
    Cancer Chemother Pharmacol; 1999; 43(1):1-7. PubMed ID: 9923534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts.
    Colbern GT; Dykes DJ; Engbers C; Musterer R; Hiller A; Pegg E; Saville R; Weng S; Luzzio M; Uster P; Amantea M; Working PK
    Clin Cancer Res; 1998 Dec; 4(12):3077-82. PubMed ID: 9865923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulations.
    Ballerini A; Moro F; Nerini IF; Marzo CM; Di Clemente A; Ferrari M; D'Incalci M; Biondi A; Colombini A; Conter V; Porcu L; Cervo L; Rizzari C; Zucchetti M
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1267-1271. PubMed ID: 28424964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
    Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary in vivo evaluation of the protein transduction domain-modified ATTEMPTS approach in enhancing asparaginase therapy.
    Li YT; Kwon YM; Spangrude GJ; Liang JF; Chung HS; Park YJ; Yang VC
    J Biomed Mater Res A; 2009 Oct; 91(1):209-20. PubMed ID: 18814276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation.
    Coimbra M; Banciu M; Fens MH; de Smet L; Cabaj M; Metselaar JM; Storm G; Schiffelers RM
    J Control Release; 2010 Dec; 148(3):303-10. PubMed ID: 20869410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
    Avramis VI; Martin-Aragon S; Avramis EV; Asselin BL
    Anticancer Res; 2007; 27(4C):2561-72. PubMed ID: 17695416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL).
    Kwon YM; Chung HS; Moon C; Yockman J; Park YJ; Gitlin SD; David AE; Yang VC
    J Control Release; 2009 Nov; 139(3):182-9. PubMed ID: 19577600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models.
    Tardi P; Choice E; Masin D; Redelmeier T; Bally M; Madden TD
    Cancer Res; 2000 Jul; 60(13):3389-93. PubMed ID: 10910044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
    Kong G; Anyarambhatla G; Petros WP; Braun RD; Colvin OM; Needham D; Dewhirst MW
    Cancer Res; 2000 Dec; 60(24):6950-7. PubMed ID: 11156395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposomal encapsulation of the natural flavonoid fisetin improves bioavailability and antitumor efficacy.
    Seguin J; Brullé L; Boyer R; Lu YM; Ramos Romano M; Touil YS; Scherman D; Bessodes M; Mignet N; Chabot GG
    Int J Pharm; 2013 Feb; 444(1-2):146-54. PubMed ID: 23380621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
    Khan MA; Owais M
    J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved pharmacodynamics of L-asparaginase-loaded in human red blood cells.
    Kravtzoff R; Desbois I; Lamagnere JP; Muh JP; Valat C; Chassaigne M; Colombat P; Ropars C
    Eur J Clin Pharmacol; 1996; 49(6):465-70. PubMed ID: 8706771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor activity of liposomal glucocorticoids: The relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity.
    Kluza E; Yeo SY; Schmid S; van der Schaft DW; Boekhoven RW; Schiffelers RM; Storm G; Strijkers GJ; Nicolay K
    J Control Release; 2011 Apr; 151(1):10-7. PubMed ID: 21130819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.